Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

被引：22
|
作者：
Dal Molin, Graziela Z. [1 ]
Omatsu, Kohei [2 ]
Sood, Anil K. [1 ]
Coleman, Robert L. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, 1155 Herman Pressler Dr,CPB 6-3590, Houston, TX 77030 USA
[2] Canc Inst Hosp, Dept Gynecol, Tokyo, Japan
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2018年 / 10卷
关键词：
BRCA; ovarian cancer; PARP; PARP inhibitors; platinum-sensitive ovarian cancer; rucaparib; Rubraca; RECURRENT EPITHELIAL OVARIAN; RIBOSE POLYMERASE INHIBITOR; PARP INHIBITOR; FALLOPIAN-TUBE; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; PRIMARY PERITONEAL; BRCA2; MUTATIONS; SEROUS OVARIAN;
D O I：
10.1177/1758835918778483
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Evaluation of rucaparib and companionydiagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy
    Jenner, Zachary B.
    Sood, Anil K.
    Coleman, Robert L.
    FUTURE ONCOLOGY, 2016, 12 (12) : 1439 - 1456
  • [2] The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer
    Nirsimloo, Rachel
    Gourley, Charlie
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (06) : 597 - 603
  • [3] The forefront of ovarian cancer therapy: update on PARP inhibitors
    Mirza, M. R.
    Coleman, R. L.
    Gonzalez-Martin, A.
    Moore, K. N.
    Colombo, N.
    Ray-Coquard, I
    Pignata, S.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1148 - 1159
  • [4] How safe is rucaparib in ovarian cancer?
    Cosgrove, Casey M.
    O'Malley, David M.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1249 - 1255
  • [5] Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
    Pearre, Diana C.
    Tewari, Krishnansu S.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 2189 - 2201
  • [6] Rucaparib for the treatment of ovarian cancer
    Cyriac, Sunu Lazar
    Karakasis, Katherine
    Oza, Amit M.
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (02): : 151 - 161
  • [7] Rucaparib in the landscape of PARP inhibition in ovarian cancer
    Colomba, Emeline
    Pautier, Patricia
    Pommeret, Fanny
    Leary, Alexandra
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 437 - 446
  • [8] Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease
    Dal Molin, Graziela Z.
    Westin, Shannon N.
    Coleman, Robert L.
    FUTURE ONCOLOGY, 2018, 14 (30) : 3101 - 3110
  • [9] An update on the safety of olaparib for treating ovarian cancer
    Cottrell, Kelsi
    Clark, Caroline L.
    Penson, Richard T.
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (04) : 447 - 451
  • [10] Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
    Xie, Yao
    Zhou, Fei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345